The Japanese patent office has granted key patent covering covering CEL-SCI Corporation's investigational cancer drug, Multikine (Leukocyte Interleukin, Injection). The patent, Japanese patent number 5,122,279, is titled, "A Method of Pre-Sensitizing Cancer Prior to Treatment with Radiation and/or Chemotherapy and a Novel Cytokine Mixture".

Key patents on multikine have now been issued in the largest pharmaceutical markets in the world: the United States, European Union, China and Japan.

This invention relates to a novel effect of Multikine observed during clinical trials that CEL-SCI believes indicates it has the potential to pre-sensitize cancer cells to a therapeutic treatment such as chemotherapy, radiation therapy or immunotherapy. Phase I and II clinical studies with multikine demonstrated that multikine induced cancerous cells to enter into the cell cycle phase, and thereby possibly increased their vulnerability to chemotherapy and radiation therapy. Further research is required and currently underway in CEL-SCI's phase III clinical trial in an effort to confirm the observed potential synergies of multikine.

Head and neck cancer accounts for about six per cent of the world's cancer cases, for a total of about 650,000 new cases every year and is associated mainly with excessive alcohol and tobacco use. Many head and neck cancers are also associated with and are thought to be caused by the Human Pappiloma Virus (HPV), the same virus that causes cervical cancer.

Multikine, an investigational immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines and colony-stimulating factors, is currently being developed for treatment of head and neck cancer.

Multikine is the first immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of the Company's clinical development programme, multikine would become an additional and different kind of therapy in the fight against cancer: one that employs the body's natural ability to fight tumours.

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.